Bizily Scott 4

What Happened

• Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics (FDMT), exercised stock options to acquire 9,810 shares at $4.14 per share (cost $40,613) and then sold those 9,810 shares in the open market at $12.00 per share for total proceeds of $117,720 on June 23, 2026. The filing also reports a derivative disposition at $0 associated with the option conversion/exercise.

Key Details

• Transaction date: June 23, 2026 (Form 4 filed June 25, 2026)
• Exercise (Code M): 9,810 shares acquired at $4.14 each — $40,613 total cost
• Sale (Code S): 9,810 shares sold at $12.00 each — $117,720 total proceeds
• Derivative line: 9,810 shares disposed at $0, reflecting conversion/exercise of the option
• Shares owned after transaction: Not disclosed in this filing
• Footnotes:
  • F1: Reflects 5,023 shares purchased under the company Employee Stock Purchase Plan (Rule 16b-3 exemption).
  • F2: The option subject to exercise vests monthly (1/48 per month) beginning March 6, 2025; fully vested after four years if service continues.
• Filing timeliness: Reported on the SEC on June 25, 2026 (two days after the trade date).

Context

• This was an option exercise followed by an immediate sale of the exercised shares (a cashless-style outcome). Such transactions commonly occur for liquidity or tax-payment reasons and are not, by themselves, a clear signal of the insider’s view on the company.
• Transaction codes: M = exercise/conversion of derivative; S = sale in open market.